OptimizeRx (OPRX) Cash from Financing Activities (2010 - 2026)

OptimizeRx (OPRX) has 13 years of Cash from Financing Activities data on file, last reported at -$2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 361.33% year-over-year to -$2.7 million; the trailing twelve-month figure through Mar 2026 stood at -$10.9 million (down 124.76% YoY), and the FY2025 full-year result was -$8.8 million, down 79.15% from the prior year.
• Cash from Financing Activities grew to -$2.7 million in Q1 2026, from -$3.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $36.2 million in Q4 2023 to a low of -$12.0 million in Q3 2022.
• A 5-year average of -$420457.5 and a median of -$640000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 586.46% in 2023, while the deepest fall reached 3080.6% in 2023.
• Tracing OPRX's Cash from Financing Activities over 5 years: stood at -$7.4 million in 2022, then soared by 586.46% to $36.2 million in 2023, then sank by 107.8% to -$2.8 million in 2024, then fell by 22.1% to -$3.4 million in 2025, then gained by 21.46% to -$2.7 million in 2026.
• Business Quant data shows OPRX's Cash from Financing Activities at -$2.7 million in Q1 2026, -$3.4 million in Q4 2025, and -$258000.0 in Q3 2025.